[1]
|
Rollig, C., Knop, S. and Bornhauser, M. (2015) Multiple Myoloma. Lancet, 385, 2197-2208.
https://doi.org/10.1016/S0140-6736(14)60493-1
|
[2]
|
Dhakal, B., Szabo, A., Chhabra, S., Hamadani, M., D’Souza, A., Usmani, S.Z., et al. (2018) Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-Analysis. JAMA Oncology, 4, 343-350. https://doi.org/10.1001/jamaoncol.2017.4600
|
[3]
|
Mateos, M.V., Goldschmidt, H., San-Miguel, J., Mikhael, J., DeCosta, L., Zhou, L., et al. (2018) Carfilzomib in Relapsed or Refractory multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: A Subgroup Analysis of the Randomized Phase 3 ASPIRE and ENDEA VOR Trials. Hematological oncology, 36, 463-470.
https://doi.org/10.1002/hon.2499
|
[4]
|
Krishnan, A., Kapoor, P., Palmer, J.M., Tsai, N.-C., Kumar, S., Lonial, S., et al. (2018) Phase I/II Trial of the Oral Regimen Ixazomib, Pomalidomide, and Dexamethasone in Relapsed/Refractory multiple Myeloma. Leukemia, 32, 1567-1574.
https://doi.org/10.1038/s41375-018-0038-8
|
[5]
|
Anderson, K.C. (2016) Progress and Paradigms in Multiple Myeloma. Clinical Cancer Research, 22, 5419-5427.
https://doi.org/10.1158/1078-0432.CCR-16-0625
|
[6]
|
Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., et al. (2013) Chimeric Antigen Receptor—Modified T Cells for Acute Lymphoid Leukemia. New England Journal of Medicine, 368, 1509-1518. https://doi.org/10.1056/NEJMoa1215134
|
[7]
|
Porter, D.L., Levine, B.L., Kalos, M., Bagg, A. and June, C.H. (2011) Chimeric Antigen Receptor—Modified T Cells for Acute Lymphoid Leukemia. New England Journal of Medicine d, 365, 725-733.
https://doi.org/10.1056/NEJMoa1103849
|
[8]
|
Rasche, L., Chavan, S.S., Stephens, O.W., Patel, P.H., Tytarenko, R., Ashby, C., et al. (2017) Spatial Genomic Heterogeneity in Multiple Myeloma Revealed by Multi-Region Sequencing. Nature Communications, 8, Article No. 268.
https://doi.org/10.1038/s41467-017-00296-y
|
[9]
|
Zeisberg, M. and Neilson, E.G. (2009) Biomarkers for Epithelial-Mesenchymal Transitions. Journal of Clinical Investigation, 119, 1429-1437. https://doi.org/10.1172/JCI36183
|
[10]
|
Wang, Q., Li, H., Sun, Z., Dong, L., Gao, L., Liu, C., et al. (2016) Kukoamine A Inhibits Human Glioblastoma Cell Growth and Migration through Apoptosis Induction and Epithelial-Mesenchymal Transition Attenuation. Scientific Reports, 6, Article No. 36543. https://doi.org/10.1038/srep36543
|
[11]
|
Wang, N., He, Y.L., Pang, L.J., Zou, H., Liu, C.-X., Zhao, J., et al. (2015) Down-Regulated E-Cadherin Expression Is Associated with Poor Five-Year Overall Survival in Bone and Soft Tissue Sarcoma: Results of a Meta-Analysis. PLoS ONE, 10, Article ID: e0121448. https://doi.org/10.1371/journal.pone.0121448
|
[12]
|
Shi, X., Ying, L., Zhou, X., et al. (2016) Downregulation of Metadherin Inhibits the Invasiveness of Diffuse Large B Cell Lymphoma. International Journal of Clinical and Experimental Pathology, 9, 8112-8121.
|
[13]
|
Stavropoulou, V., Kaspar, S., Brault, L., Sanders, M.A., Juge, S, Morettini, S., et al. (2016) MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome. Cancer Cell, 30, 43-58. https://doi.org/10.1016/j.ccell.2016.05.011
|
[14]
|
Kahlert, U.D., Joseph, J.V. and Kruyt, F.A.E. (2017) EMT- and MET-Related Processes in Nonepithelial Tumors: Importance for Disease Progression, Prognosis, and Therapeutic Opportunities. Molecular Oncology, 11, 860-877.
https://doi.org/10.1002/1878-0261.12085
|
[15]
|
Azab, A.K., Hu, J., Quang, P., Azab, F., Pitsillides, C., Awwad, R., et al. (2012) Hypoxia Promotes Dissemination of Multiple Myeloma through Acquisition of Epithelial to Mesenchymal Transition-Like Features. Blood, 119, 5782-5794.
https://doi.org/10.1182/blood-2011-09-380410
|
[16]
|
Yang, J., Lian, W., Sun, L., Qi, D., Ding, Y. and Zhang, X.-H. (2016) High Nuclear Expression of Twist1 in the Skeletal Extramedullary Disease of Myeloma Patients Predicts Inferior Survival. Pathology—Research and Practice, 212, 210-216. https://doi.org/10.1016/j.prp.2015.12.011
|
[17]
|
Roccaro, A.M., Mishima, Y., Sacco, A., Moschetta, M., Tai, Y.-T., Shi, J., et al. (2015) CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-Like Transcriptional Activation. Cell Report, 12, 622-635. https://doi.org/10.1016/j.celrep.2015.06.059
|
[18]
|
Lv, C., Dai, H., Sun, M., Zhao, H., Wu, K., Zhu, J., et al. (2017) Mesenchymal Stem Cells Induce Epithelial Mesenchymal Transition in Melanoma by Paracrine Secretion of Transforming Growth Factor-β. Melanoma Research, 27, 74-84. https://doi.org/10.1097/CMR.0000000000000325
|
[19]
|
Nishimura, K., Semba, S., Aoyagi, K., Sasaki H. and Yokozaki, H. (2012) Mesenchymal Stem Cells Provide an Advantageous Tumor Microenvironment for the Restoration of Cancer Stem Cells. Pathobiology, 79, 290-306.
https://doi.org/10.1159/000337296
|
[20]
|
Ibraheem, A., Attar-Schneider, O., Dabbah, M., Jarchowsky, O.D., Matalon, S.T., Lishner, M., et al. (2019) BM-MSCs-Derived ECM Modifies Multiple Myeloma Phenotype and Drug Response in a Source-Dependent Manner. Translational Research, 207, 83-95. https://doi.org/10.1016/j.trsl.2019.01.003
|
[21]
|
Zhou, Y. (2019) Study the Effects of BM-MSCs-Derived Exosomes on EMT-Like Phenotype, Stemness and Invasion of Myeloma Cells. Master’s Thesis, Tianjin Medical University, Tianjin.
|
[22]
|
Huang, Z., Liang, X., Wu, W., Chen, X., Zeng, Q., Yang, M., et al. (2019) Mechanisms Underlying the Increased Chemosensitivity of Bortezomib-Resistant Multiple Myeloma by Silencing Nuclear Transcription Factor Snail1. Oncology Reports, 41, 415-426. https://doi.org/10.3892/or.2018.6797
|
[23]
|
DeCraene, B. and Berx, G. (2013) Regulatory Networks Defining EMT during Cancer Initiation and Progression. Nature Reviews Cancer, 13, 97-110. https://doi.org/10.1038/nrc3447
|
[24]
|
Michela, F. and Giovanni, T. (2020) WNT Signaling in Hematological Malignancies. Frontiers in Oncology, 10, Article ID: 615190. https://doi.org/10.3389/fonc.2020.615190
|
[25]
|
Derksen, P.W., Tjin, E., Meijer, H.P., Klok, M.D., Mac Gillavry, H.D., van Oers, M.H.J., et al. (2004) Illegitimate WNT Signaling Promotes Proliferation of Multiple Myeloma Cells. Proceedings of the National Academy of Sciences of the United States of America, 101, 6122-6127. https://doi.org/10.1073/pnas.0305855101
|
[26]
|
Baron, R. and Kneissel, M. (2013) WNT Signaling in Bone Homeostasis and Disease: From Human Mutations to Treatments. Nature Medicin, 19, 179-192. https://doi.org/10.1038/nm.3074
|
[27]
|
Huang, H.J., Zhou, L.L., Fu, W.J., et al. (2015) β-Catenin SUMOylation is Involved in the Dysregulated Proliferation of Myeloma Cells. American Journal of Cancer Research, 5, 309-320.
|
[28]
|
Driscoll, J.J., Pelluru, D., Lefkimmiatis, K., Fulciniti, M., Prabhala, R.H., Greipp, P.R., et al. (2010) The Sumoylation Pathway Is Dysregulated in Multiple Myeloma and is Associated with Adverse Patient Outcome. Blood, 115, 2827-2834. https://doi.org/10.1182/blood-2009-03-211045
|
[29]
|
Bjorklund, C.C., Ma, W., Wang, Z.Q., Eric Davis, R., Kuhn, D.J., Kornblau, S.M., et al. (2011) Evidence of a Role for Activation of Wnt/Beta-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide. Journal of Biological Chemistrym, 286, 11009-11020. https://doi.org/10.1074/jbc.M110.180208
|
[30]
|
Bjorklund, C.C., Baladandayuthapani, V., Lin, H.Y., Jones, R.J., Kuiatse, I., Wang, H., et al. (2014) Evidence of a Role for CD44 and Cell Adhesion in Mediating Resistance to Lenalidomide in Multiple Myeloma: Therapeutic Implications. Leukemia, 28, 373-383. https://doi.org/10.1038/leu.2013.174
|
[31]
|
Valenta, T., Hausmann, G. and Basler, K. (2012) The Many Faces and Functions of β-Catenin. The EMBO Journal, 31, 2714-2736. https://doi.org/10.1038/emboj.2012.150
|
[32]
|
Ma Y., Zhang, P., Zhang, Q., Wang, X., Miao, Q., Lyu, X., et al. (2021) Dihydroartemisinin Suppresses Proliferation, Migration, the Wnt/β-Catenin Pathway and EMT via TNKS in Gastric Cancer. Oncology Letters, 22, Article No. 688.
https://doi.org/10.3892/ol.2021.12949
|
[33]
|
Jin, X., Yin, J., Zhu, H., Li, W., Yu, K., Liu, M., et al. (2021) SMG9 Serves as an Oncogene to Promote the Tumor Progression via EMT and Wnt/β-Catenin Signaling Pathway in Hepatocellular Carcinoma. Frontiers in Pharmacology, 12, Article ID: 701451. https://doi.org/10.3389/fphar.2021.701454
|
[34]
|
Liu, W., Fu, X. and Li, R. (2021) CNN1 Regulates the DKK1/Wnt/βcatenin/cmyc Signaling Pathway by Activating TIMP2 to Inhibit the Invasion, Migration and EMT of Lung Squamous Cell Carcinoma Cells. Experimental and Therapeutic Medicine, 22, Article No. 855. https://doi.org/10.3892/etm.2021.10287
|
[35]
|
Guo, B., Xiao, C., Liu, Y., Zhang, N., Bai, H., Yang, T., et al. (2021) MiR-744-5p Inhibits Multiple Myeloma Proliferation, Epithelial Mesenchymal Transformation and Glycolysis by Targeting SOX12/Wnt/β-Catenin Signaling. OncoTargets and Therapy, 14, 1161-1172. https://doi.org/10.2147/OTT.S270636
|